A5009298204- Radiopharmaceutical Chemistry and Applications
- Glioma Diagnosis and Treatment
- Cerebrospinal fluid and hydrocephalus
- Intracranial Aneurysms: Treatment and Complications
- Medical Imaging Techniques and Applications
- Traumatic Brain Injury and Neurovascular Disturbances
- Boron Compounds in Chemistry
- Cerebrovascular and Carotid Artery Diseases
- Neurosurgical Procedures and Complications
- Cardiac electrophysiology and arrhythmias
- Lysosomal Storage Disorders Research
- Intracerebral and Subarachnoid Hemorrhage Research
- Vascular Malformations Diagnosis and Treatment
- Mechanical Circulatory Support Devices
- Acute Ischemic Stroke Management
- Cardiac Imaging and Diagnostics
- Advanced MRI Techniques and Applications
- Pulmonary Hypertension Research and Treatments
- Meningioma and schwannoma management
- Trypanosoma species research and implications
- Cardiac Arrest and Resuscitation
- Cardiac Arrhythmias and Treatments
- Urinary Tract Infections Management
- Amyotrophic Lateral Sclerosis Research
- Vascular Anomalies and Treatments
Southern Tohoku General Hospital
1989-2023
Teikyo University Chiba Medical Center
2019
Nagoya Central Hospital
2014-2018
Nagoya University
2014
Osaka Kyoiku University
2011
Hiroshima University
1998
Showa University
1982
Boron neutron capture therapy (BNCT) utilizes tumor-selective particle radiation. This study aimed to assess the safety and efficacy of accelerator-based BNCT (AB-BNCT) using a cyclotron-based generator (BNCT 30) 10B-boronophenylalanine (SPM-011) in patients with recurrent malignant glioma (MG) (primarily glioblastoma [GB]).This multi-institutional, open-label, phase II clinical trial involved 27 MG cases, including 24 GB who were enrolled from February 2016 June 2018. The was conducted...
This study was conducted to elucidate the pathologic conditions of cerebral circulatory disorders in idiopathic normal pressure hydrocephalus (iNPH). Among 44 possible iNPH patients, 40 patients underwent shunt surgery based on diagnostic flow charts plotted by Southern Tohoku method and were evaluated be shunt-effective at end first post-surgical month. The blood (CBF) measured N-isopropyl-(123I)-P-iodo-amphetamine single photon emission computed tomography (mean, mCBF; cortical region,...
Background For pituitary tumors, positron emission tomography (PET) with 11C-methonine (MET) has been reported as feasible to facilitate diagnosis. MET is well-known accumulate in the normal glands, but almost no studies have examined degree of accumulation gland. Purpose To investigate gland on PET/CT. Material and Methods Among patients who underwent PET/CT using over past 7 years, 77 fulfilled our criteria for glands were retrospectively selected. Maximum standardized uptake value...
Objective The aim of this study was to determine the assessment positron emission tomography–computed tomography using 11 C-methionine (MET PET/CT) for World Health Organization (WHO) grades II and III meningiomas; MET PET/CT compared with 18 F-fluorodeoxy glucose (FDG PET/CT). Methods This performed in 17 cases residual and/or recurrent WHO meningiomas. Two neuroradiologists reviewed both scans. For agreement, κ coefficient measured. Difference tumor-to-normal brain uptake ratios (T/N...
Background: Fabry disease is an X-linked lysosomal storage disorder and shows globotriosylceramide (Gb3) accumulation in multiple organs, resulting from a deficiency of α-galactosidase. In patients with disease, cardiovascular occurs at early age. Previous studies have shown that serum levels high-density lipoprotein-cholesterol (HDL-C) increase this yet its clinical significance for remains unclear.
Enzyme replacement therapy (ERT) is the only approved for Fabry disease. In June 2009, there was a worldwide shortage of agalsidase beta, necessitating dose reductions or switching to alfa in some patients.We present two cases disease (a parent and child) who received beta 27 months at licensed 10 reduced dose, followed by switch 28 months. Case 1, 26-year-old male had severe coughing fatigue during ERT with requiring antitussive asthmatic drug therapy. After alfa, gradually resolved...
2536 Background: Boron neutron capture therapy (BNCT) is tumor-selective particle radiation and theoretically efficacious especially for tumors with infiltrative nature, such as glioblastoma (GBM). The aim of this study to assess safety efficacy accelerator-based BNCT (AB-BNCT) using cyclotron-based generator, BNCT30, 10 B-boronophenylalanine (borofalan( B)) agent, SPM-011, in patients recurrent malignant gliomas, chiefly GBM. Methods: multi-institutional open-label, phase II clinical trial...
Background Positron emission tomography (PET) findings for gliomatosis and lymphomatosis have been rarely reported. Purpose To compare PET/computed (CT) using 11 C-methionine (MET) from PET/CT 18 F-fluorodeoxy glucose (FDG) patients with or of the brain. Material Methods Participants comprised all 10 brain treated at our institution in past 12 years. Underlying pathologies intravascular lymphoma (n = 1), 3), 6). All cases were pathologically diagnosed. In seven patients, both MET-PET/CT...
The use of propranolol is generally contraindicated in patients with congestive heart failure. However, we successfully used a continuous high-dose infusion propranolol, combination the extracorporeal life support (ECLS) and intra-aortic balloon pumping (IABP), to treat refractory life-threatening ventricular tachycardia patient postoperative early combined ECLS IABP before irreversible myocardial damage contributed successful outcome.
ドック受診者の長期追跡調査を基に未破裂脳動脈瘤の保有率と破裂率を求め, その取り扱いについて考察した.対象は1993年7月〜2003年12月までにMRAを受けた9,641名のうち脳動脈瘤を認めた156例である.未破裂脳動脈瘤の保有率は1.6%と従来の報告より低めの値であり, 大きさは, 3〜7mmが78.7%を占めた.予防的処置を行わなかった121例の観察期間中6例(平均観察期間4.7年)に破裂を認め, Kaplan-Meier法による累積破裂率は, 1年で1.9% (3年: 4.6%, 5年: 8.5%)であった.また, 破裂6例中5例が7mm以下の脳動脈瘤であった.2003年のISUIAの研究によると, 破裂率は脳動脈瘤の大きさに関連し, 10mm未満でも7mmより大きいものは年間0.7%の確率で破れること, また6mm以下では年率約0.1%と破裂リスクは低いと述べている.しかし今回のわれわれの研究によれば, 日本人の脳動脈瘤は欧米人に比べ小さなものが多く, 小さなうちにより高い確率で破裂する可能性が示唆された.
Either single (50mg) or multiple (25mg/day × 4 days) dose of etretinate was administered orally into 5 healthy volunteers once a day 30 minutes after breakfast.After the administration with 50mg initial 25mg, AUC (Area Under Curve) blood level unchanged 1, 305 ng · Ehr/ml and 267 Ehr /ml 25mg. The approximate half-life 2 hr 25 mg 3.6 50mg. main metabolite, Ro 10-1670, 2.7 times as large that first mg, but merely 1.5 25mg.On th mg/day, became 1.6 1st day, metabolite decreased on down to 61%...
Abstract PURPOSE Accelerator-based neutron sources have received regulatory approval and boron capture therapy (BNCT) for head neck cancer has been introduced into clinical treatment in earnest. BNCT is a radiotherapy with cell-selective characteristics, its application to highly invasive malignant gliomas (MG) the origin of development. This study reports long-term results phase II accelerator-based (AB-BNCT) using cyclotron-based source (BNCT30) boronophenylalanine product (SPM-011)...